Properties of intraepithelial neoplasia relevant to the development of cancer chemopreventive agents

✍ Scribed by Boone, Charles W.; Bacus, James W.; Bacus, James V.; Steele, Vernon E.; Kelloff, Gary J.

• Publisher: John Wiley and Sons
• Year: 1997
• Tongue: English
• Weight: 455 KB
• Volume: 67
• Category: Article
• ISSN: 0730-2312
• DOI: 10.1002/(sici)1097-4644(1997)28/29+<1::aid-jcb3>3.0.co;2-y

✦ Synopsis

Cancer chemoprevention is concerned with the development of drugs or diet supplements that will avert the onset or stop the progression of the intraepithelial neoplasia which precedes invasive cancer. Two basic processes underlie the onset and development of intraepithelial neoplasia. First is genomic instability (often associated with chronic diffuse epithelial hyperplasia), which is the increased production of genomic structural variants due to unrepaired DNA breaks with secondary formation of abnormal structures, including ''mutator'' mutations in genes responsible for genomic stability, gene copy amplification or loss from DNA breakage-fusion-anaphase bridge cycles, unequal sister chromatid exchange, and accumulation of double minutes. Second is the development within an epithelium having genomic instability of multicentric neoplastic lesions that independently progress through each of the following processes at a continuously accelerating rate: clonal evolution, hyperproliferation, production of genomic structural variants, and apoptosis. Recommended chemoprevention strategies based on these mechanisms are (1) early diagnosis and treatment of genomic instability before the appearance of intraepithelial neoplasia, i.e., during the ''predysplastic'' or ''premorphologic'' phase, (2) development of multiple agents that block intralesional proliferation at steps along the ''command'' pathways of mitotic signal transduction and along the ''execute'' pathways of synthesis of daughter cell components, (3) development of nontoxic antiinflammatory agents, antioxidants, antimutagens, and proapoptotics, (4) avoidance of ''clonal escape'' through use of drug combinations, and (5) use of computer-assisted quantitative image analysis to assay modulation of surrogate endpoints in chemoprevention clinical trials.